Coverage
-
November 16, 2015
A California federal court's decision for drugmakers in multidistrict litigation over their alleged failure to warn of their Type 2 diabetes drugs' potential to cause pancreas problems is among the first to clarify in detail that the U.S. Food and Drug Administration need not explicitly reject a heightened warning in order for branded-drug companies to beat labeling claims by injured patients.
5 other articles on this case.
View all »